Tuesday, December 10, 2024

QIAGEN Expands QIAstat-Dx with New Barcelona Site

QIAGEN announced plans to move its QIAstat-Dx operations within the Barcelona area to a new site in Esplugues de Llobregat as part of a multi-year investment to strengthen this business.

Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of respiratory, gastrointestinal and meningitis / encephalitis conditions.

QIAstat-Dx is also being developed for use in precision medicine, in particular to support the expansion of recent partnerships announced with Eli Lilly and AstraZeneca. In precision medicine applications, QIAstat‑Dx for instance enables specialty care providers to perform genotyping whilst patients undergo routine clinical examination, thus enabling fast decision-making for potential suitability for certain genomically targeted medicines.

The new site builds on the long-standing presence of QIAGEN in the Barcelona area. Teams at the site will include Research & Development, Manufacturing, Sales, Marketing, Quality Assurance and Regulatory Affairs. In addition, it will serve as a center of excellence for R&D in microfluidics, as well as system and assay development.

Also Read: Adcendo ApS Secures $135M in Oversubscribed Series B for ADC Pipeline

“QIAstat-Dx demonstrated its value during the COVID-19 pandemic, supporting healthcare providers with rapid syndromic testing and crucial information when time mattered most,” said Thierry Bernard, CEO of QIAGEN. “Now we are building on this success by expanding the QIAstat-Dx pipeline to address a broader spectrum of healthcare needs. This means both expanding the range of pathogens for infectious disease testing as well as developing solutions for other disease areas and precision medicine applications.”

Barcelona provides an ideal location for this expansion, combining access to scientific talent with a robust ecosystem that includes universities, research institutions, start-ups, and well established pharma and life science companies.

QIAGEN can also build on the local expertise in the QIAstat-Dx technology, which was originally developed by a start-up from Barcelona and acquired by QIAGEN in 2018.

The Esplugues de Llobregrat site will enable QIAGEN to advance diagnostic capabilities in infectious diseases and beyond, helping to meet the growing demand for rapid diagnostics in diverse healthcare settings, from hospitals and clinics to decentralized testing points. The site will span 8,000 square meters and include offices, manufacturing lines, clean rooms, laboratories and logistics areas. The base building of the new facility has received LEED Platinum Certification, the highest standard in energy-efficient and environmentally responsible building design. The fit-out of the new facility will also meet this high standard and will be equipped with digitalized production lines.

SOURCE: Businesswire

Subscribe Now

    Hot Topics